CO2023012549A2 - Monoclonal antibody or antigen-binding fragment thereof that specifically binds to gd2 (gd2 ganglioside), and use thereof - Google Patents

Monoclonal antibody or antigen-binding fragment thereof that specifically binds to gd2 (gd2 ganglioside), and use thereof

Info

Publication number
CO2023012549A2
CO2023012549A2 CONC2023/0012549A CO2023012549A CO2023012549A2 CO 2023012549 A2 CO2023012549 A2 CO 2023012549A2 CO 2023012549 A CO2023012549 A CO 2023012549A CO 2023012549 A2 CO2023012549 A2 CO 2023012549A2
Authority
CO
Colombia
Prior art keywords
ganglioside
antigen
binding fragment
specifically binds
monoclonal antibody
Prior art date
Application number
CONC2023/0012549A
Other languages
Spanish (es)
Inventor
Dmitry Valentinovich Morozov
Sergei Andreevich Ageev
Valery Vladimirovich Solovyev
Pavel Andreevich Iakovlev
Yulia Sergeevna Chernykh
Diana Aleksandrovna Kondinskaia
Valeriia Evgenevna Shigina
Dina Khaidarovna Sakharova
Mariia Anatolevna Grefenshtein
Alina Konstantinovna Stolyarova
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2021107773A external-priority patent/RU2796937C2/en
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of CO2023012549A2 publication Critical patent/CO2023012549A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere al campo de la biotecnología y la medicina, en particular a un anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente al GD2 (gangliósido GD2). La invención se refiere además a ácidos nucleicos que codifican dicho anticuerpo, vectores de expresión, células huésped y métodos para producirlos, métodos para producir los anticuerpos según la invención, composiciones farmacéuticas que comprenden el anticuerpo según la invención, composiciones farmacéuticas que comprenden el anticuerpo según la invención y otros compuestos terapéuticamente activos, métodos para tratar enfermedades o trastornos mediados por GD2, usos de los anticuerpos o composiciones farmacéuticas de los mismos para tratar enfermedades o trastornos mediados por GD2, y usos de los anticuerpos y otros compuestos terapéuticamente activos para tratar enfermedades o trastornos mediados por GD2.The present invention relates to the field of biotechnology and medicine, in particular to a monoclonal antibody or antigen-binding fragment thereof that specifically binds to GD2 (GD2 ganglioside). The invention further relates to nucleic acids encoding said antibody, expression vectors, host cells and methods for producing them, methods for producing the antibodies according to the invention, pharmaceutical compositions comprising the antibody according to the invention, pharmaceutical compositions comprising the antibody according to the invention and other therapeutically active compounds, methods for treating GD2-mediated diseases or disorders, uses of the antibodies or pharmaceutical compositions thereof for treating GD2-mediated diseases or disorders, and uses of the antibodies and other therapeutically active compounds for treating diseases or GD2-mediated disorders.

CONC2023/0012549A 2021-03-24 2023-09-22 Monoclonal antibody or antigen-binding fragment thereof that specifically binds to gd2 (gd2 ganglioside), and use thereof CO2023012549A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2021107773A RU2796937C2 (en) 2021-03-24 Monoclonal antibody or its antigen-binding fragment which specifically binds to gd2 (gd2 ganglioside) and its use
PCT/RU2022/050096 WO2022203552A1 (en) 2021-03-24 2022-03-24 Monoclonal antibody that specifically binds to gd2

Publications (1)

Publication Number Publication Date
CO2023012549A2 true CO2023012549A2 (en) 2023-10-09

Family

ID=83395963

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0012549A CO2023012549A2 (en) 2021-03-24 2023-09-22 Monoclonal antibody or antigen-binding fragment thereof that specifically binds to gd2 (gd2 ganglioside), and use thereof

Country Status (10)

Country Link
CN (1) CN117677695A (en)
AR (1) AR125219A1 (en)
CL (1) CL2023002843A1 (en)
CO (1) CO2023012549A2 (en)
CR (1) CR20230456A (en)
EC (1) ECSP23072412A (en)
MX (1) MX2023011246A (en)
TW (1) TW202304989A (en)
UY (1) UY39687A (en)
WO (1) WO2022203552A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005070967A2 (en) * 2004-01-22 2005-08-04 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
NZ603581A (en) * 2010-06-19 2015-05-29 Sloan Kettering Inst Cancer Anti-gd2 antibodies
WO2014144763A2 (en) * 2013-03-15 2014-09-18 Memorial Sloan Kettering Cancer Center High affinity anti-gd2 antibodies

Also Published As

Publication number Publication date
CR20230456A (en) 2023-12-13
UY39687A (en) 2022-08-31
CL2023002843A1 (en) 2024-03-22
WO2022203552A1 (en) 2022-09-29
CN117677695A (en) 2024-03-08
ECSP23072412A (en) 2023-10-31
MX2023011246A (en) 2023-10-30
AR125219A1 (en) 2023-06-28
TW202304989A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
PE20211284A1 (en) ANTI-NKG2A ANTIBODIES AND USES OF THEM
RU2018139811A (en) MULTI-SPECIFIC ANTI-BINDING CONSTRUCTIONS TARGETING IMMUNOTHERAPEUTIC MEANS
BR112019008010A2 (en) isolated monoclonal antibody or immunologically active fragment thereof, isolated bispecific monoclonal antibody, pharmaceutical composition, method for treating a disease in a human subject in need thereof, fusion protein, cd47 gene encoded immunodominant epitope, and biological molecule
CL2021000517A1 (en) Labeled antibody and / or fragment thereof comprising a monoclonal antibody or a fragment thereof, which specifically binds human tau; nucleic acid that encodes it; vector; cell; method of producing antibody; and use of the same to inhibit the aggregation of tau, and associated diseases (divisional application no. 202001003)
AR126019A1 (en) ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES
PE20221580A1 (en) THERAPEUTIC ANTIBODIES AND THEIR USES
PE20190440A1 (en) ALPHA-SINUCLEIN ANTIBODIES AND USES OF THE SAME
BR112015029953A2 (en) anti-tweakr antibodies and their uses
PE20191079A1 (en) IMMUNOGLOBULINS AND USES OF THEM
WO2021227307A8 (en) Anti-cd73 antibody and use thereof
BR112017027702A2 (en) Vascular Endothelial Growth Factor 2 Antireceptor Antibodies (vegfr2)
EA202192907A1 (en) MONOCLONAL ANTIBODY THAT SPECIFICLY BINDS TO GITR
Maleki et al. Large scale generation and characterization of anti-human cd34 monoclonal antibody in ascetic fluid of balb/c mice
PE20230464A1 (en) BINDING OF MULTI-SPECIFIC ANTIBODIES TO BCMA
BR112022012474A2 (en) ANTI-LILRB1 ANTIBODY, ANTIGEN BINDING FRAGMENT THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING THEM, USE OF SUCH ANTIBODY TO TREAT OR PREVENT CANCER, METHOD OF PREPARING SUCH ANTIBODY, NUCLEIC ACID MOLECULE AND RECOMBINANT CELL AND VECTOR.
CO2021008204A2 (en) Monoclonal Antibodies That Bind Specifically to the Trbv-9 Family Beta Region of the Human T-Cell Receptor, and Methods for Their Use
EP2970468A1 (en) Notch2 binding molecules for treating respiratory diseases
RU2017145662A (en) MONOCLONAL ANTIBODIES AND METHODS OF THEIR APPLICATION
Choi et al. Displaying and delivering viral membrane antigens via WW domain–activated extracellular vesicles
CO2021009689A2 (en) Monoclonal antibodies that specifically bind to the beta region of the trbv-9 family of the human T cell receptor, and methods for their use.
CO2023012549A2 (en) Monoclonal antibody or antigen-binding fragment thereof that specifically binds to gd2 (gd2 ganglioside), and use thereof
AR127635A1 (en) MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THAT SPECIFICALLY BINDS IL-4Ra, AND USE THEREOF
BR112023016574A2 (en) ANTI-TL1A ANTIBODY COMPOSITIONS AND TREATMENT METHODS IN LUNG
ECSP23097121A (en) Isolated bispecific antibody that specifically binds CD47 and PD-L1
BR112022020716A2 (en) ANTI-TUMOR ANTIBODIES ASSOCIATED WITH ANTIGEN AND THEIR USES